Caricamento quotazioni...
Previsioni
| Acquista |
1 |
| Mantieni |
1 |
| Vendi |
0 |
Notizie Vai al feed delle notizie
Allarity Therapeutics receives CLIA certification for its laboratory in Denmark
Allarity Therapeutics has received a CLIA registration certificate for its laboratory in Hørsholm, Denmark, enabling DRP® biomarker tests to be conducted internally for US-approved clinical trials. The certification is expected to shorten turnaround times, reduce long-term costs by cutting outsourcing, and support development of lead candidate Stenoparib for advanced, platinum-resistant ovarian cancer. The lab will also be able to offer DRP and laboratory services to third parties. At the same time, the company faces high cash burn; market capitalization is around $19 million and free cash flow was recently negative. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | giu 2026 | |
|---|---|---|
| Ricavi | 0 | - |
| Utile lordo | 0 | - |
| Utile netto | -2,98 Mln | 51,57% |
| EBITDA | -2,14 Mln | 9,71% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 18,95 Mln € |
Numero di azioni | 15,91 Mln |
Massimo/minimo a 52 settimane | 1,78 € - 0,66 € |
| Dividendi | No |
Beta | 0,51 |
Rapporto P/E | -1,77 |
Rapporto PEG | -0,01 |
Rapporto P/B | 6,21 |
Rapporto P/S | 63,64 |
Profilo aziendale
| Nome | Allarity Therapeutics Aktie |
| CEO | Thomas H. Jensen |
| Dipendenti | 8 |
Scopri gli asset
Gli azionisti di Allarity Therapeutics Aktie investono anche nei seguenti asset
